To the Editor Two reports published in a recent issue of JAMA Internal Medicine describe 6% to 9% lower opioid prescribing rates for Medicare and Medicaid patients in states that legalized marijuana compared with states that have not.1,2 As cautioned in the accompanying editorial, however, “cannabis policy has raced ahead of cannabis science,” and more research is necessary to determine if marijuana availability ameliorates opioid mortality (marijuana-protection hypothesis).3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bleyer A, Barnes B. Opioid Death Rate Acceleration in Jurisdictions Legalizing Marijuana Use. JAMA Intern Med. 2018;178(9):1280–1281. doi:10.1001/jamainternmed.2018.3888
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: